Literature DB >> 12244881

[Boswellic acids (components of frankincense) as the active principle in treatment of chronic inflammatory diseases].

H P T Ammon1.   

Abstract

Preparations from the gum resin of Boswellia serrata have been used as a traditional remedy in Ayurvedic medicine in India for the treatment of inflammatory diseases. Compounds from the gum with genuine antiinflammatory effects are pentacyclic triterpenes of the boswellic acid type. Boswellic acids inhibit the leukotriene biosynthesis in neutrophilic granulocytes by a non-redox, noncompetitive inhibition of 5-lipoxygenase. The effect is triggered by boswellic acids binding to the enzyme. Moreover certain boswellic acids have been described to inhibit elastase in leukocytes, to inhibit proliferation, induce apoptosis and to inhibit topoisomerases of leukoma- and glioma cell lines. A series of chronic inflammatory diseases are thought to be perpetuated by leukotrienes. In clinical trials promising results were observed in patients with rheumatoid arthritis, chronic colitis, ulcerative colitis, Crohn's disease, bronchial asthma und peritumoral brains edemas.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12244881     DOI: 10.1046/j.1563-258x.2002.02056.x

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  15 in total

1.  A boswellic acid-containing extract attenuates hepatic granuloma in C57BL/6 mice infected with Schistosoma japonicum.

Authors:  Miao Liu; Peng Chen; Berthold Büchele; Shengjian Dong; Dake Huang; Cuiping Ren; Yuxia Zhang; Xin Hou; Thomas Simmet; Jijia Shen
Journal:  Parasitol Res       Date:  2012-12-28       Impact factor: 2.289

2.  Bromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model of allergic airway disease.

Authors:  Eric R Secor; William F Carson; Michelle M Cloutier; Linda A Guernsey; Craig M Schramm; Carol A Wu; Roger S Thrall
Journal:  Cell Immunol       Date:  2005-12-06       Impact factor: 4.868

3.  Protective effect of boswellic acids versus pioglitazone in a rat model of diet-induced non-alcoholic fatty liver disease: influence on insulin resistance and energy expenditure.

Authors:  Sawsan A Zaitone; Bassant M Barakat; Shymaa E Bilasy; Manal S Fawzy; Eman Z Abdelaziz; Noha E Farag
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-02-24       Impact factor: 3.000

4.  Boswellia carterii extract inhibits TH1 cytokines and promotes TH2 cytokines in vitro.

Authors:  Marc R Chevrier; Abigail E Ryan; David Y-W Lee; Ma Zhongze; Zhang Wu-Yan; Charles S Via
Journal:  Clin Diagn Lab Immunol       Date:  2005-05

5.  Pro-inflammatory cytokine molecules from Boswellia serrate suppresses lipopolysaccharides induced inflammation demonstrated in an in-vivo zebrafish larval model.

Authors:  N Sai Supra Siddhu; Ajay Guru; Rajappan Chandra Satish Kumar; Bader O Almutairi; Mikhlid H Almutairi; Annie Juliet; Thangavel Mahalingam Vijayakumar; Jesu Arockiaraj
Journal:  Mol Biol Rep       Date:  2022-06-18       Impact factor: 2.742

Review 6.  Nutraceutical supplement in the management of tendinopathies: a systematic review.

Authors:  Federico Fusini; Salvatore Bisicchia; Carlo Bottegoni; Antonio Gigante; Fabio Zanchini; Alberto Busilacchi
Journal:  Muscles Ligaments Tendons J       Date:  2016-05-19

7.  Boswellia serrata, a potential antiinflammatory agent: an overview.

Authors:  M Z Siddiqui
Journal:  Indian J Pharm Sci       Date:  2011-05       Impact factor: 0.975

8.  Use of complementary and alternative medicine in Germany - a survey of patients with inflammatory bowel disease.

Authors:  Stefanie Joos; Thomas Rosemann; Joachim Szecsenyi; Eckhart G Hahn; Stefan N Willich; Benno Brinkhaus
Journal:  BMC Complement Altern Med       Date:  2006-05-22       Impact factor: 3.659

Review 9.  Plant Protease Inhibitors in Therapeutics-Focus on Cancer Therapy.

Authors:  Sandhya Srikanth; Zhong Chen
Journal:  Front Pharmacol       Date:  2016-12-08       Impact factor: 5.810

10.  Therapeutic Potential of Plants as Anti-microbials for Drug Discovery.

Authors:  Ramar Perumal Samy; Ponnampalam Gopalakrishnakone
Journal:  Evid Based Complement Alternat Med       Date:  2008-06-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.